Cicletanine and hypertensive retinopathy

Area of Science:

• Pharmacology
• Ophthalmology
• Cardiovascular Research

Background:

• Hypertensive retinopathy is a complication of high blood pressure, causing damage to retinal blood vessels.
• Stroke-prone spontaneously hypertensive rats (SHR-SP) are a validated model for studying hypertensive retinopathy.
• Existing treatments for hypertensive retinopathy often have limitations.

Purpose of the Study:

• To evaluate the efficacy of cicletanine, a new synthetic furopyridine antihypertensive drug, in mitigating hypertensive morphological lesions in the retina.
• To assess the impact of cicletanine on retinal vascular damage in a rat model of severe hypertension.

Main Methods:

• Experiments were conducted on 39 SHR-SP rats, divided into control and two cicletanine-treated groups (100 and 150 mg/kg).
• Rats received 1% NaCl in drinking water for 46 days, with monitoring of blood pressure, body weight, and mortality.
• Retinal tissues were examined using transmission electron microscopy to identify and quantify hypertensive lesions.

Main Results:

• Control rats exhibited significant hypertensive lesions in retinal capillaries and photoreceptor damage.
• Cicletanine treatment, at both dosages, markedly reduced the incidence and severity of these retinal lesions.
• Ultrastructural analysis revealed fewer multivesicular bodies and less vascular damage in treated groups.

Conclusions:

• Cicletanine demonstrates significant protective effects against hypertensive retinopathy in SHR-SP rats.
• The drug's ability to ameliorate retinal vascular damage suggests potential therapeutic value for hypertension-related eye conditions.
• Further research is warranted to explore cicletanine's mechanisms of action and clinical applicability.